| 1 |
Doxycycline related CNS Side Effects (Restlessness, Anxiety, Irritability, Nervousness, and Dizziness) - Recommendations for the change in Prescribing Information Leaflets (PILs) |
2026-Feb-17 |
|
562 KB |
| 2 |
Carbimazole related agranulocytosis - Recommendations for the change in Prescribing Information Leaflets (PILs) |
2026-Feb-17 |
|
518 KB |
| 3 |
Draft Guidance document for Import of In-vitro diagnostic Medical device for stakeholders comment (dated 30.01.2026) |
2026-Feb-02 |
|
2163 KB |
| 4 |
Cancellation of products underRC/COS-001655, for import of Cosmetics under Cosmetics Rules, 2020 |
2026-Jan-27 |
|
447 KB |
| 5 |
CDSCO updated list of Laboratories for conducting Performance Evaluation of In-Vitro Diagnostic Medical Device |
2026-Jan-19 |
|
608 KB |
| 6 |
Disposal/Rejection of Long-Pending Applications on Sugam Portal Awaiting Query Response |
2026-Jan-16 |
|
96 KB |
| 7 |
Risk classification list of medical devices pertaining to Oncology |
2026-Jan-02 |
|
308 KB |
| 8 |
FAQs on Drugs and Cosmetics (Compounding of Offences) Rules, 2025 |
2026-Jan-01 |
|
368 KB |
| 9 |
Guidelines on Compounding of Offences under the Drugs and Cosmetics Act, 1940 as per Drugs and Cosmetics (Compounding of Offences) Rules, 2025 |
2026-Jan-01 |
|
765 KB |
| 10 |
Compounding of Offences under the Drugs and Cosmetics Act, 1940 in accordance with the Drugs and Cosmetics (Compounding of Offences) Rules, 2025 |
2026-Jan-01 |
|
348 KB |
